- Home
- RPTX vs ANTX Comparison
RPTX vs ANTX Comparison
Compare RPTX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- ANTX
- Stock Information
- Founded
- RPTX 2016
- ANTX 2017
- Country
- RPTX Canada
- ANTX United States
- Employees
- RPTX N/A
- ANTX N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- ANTX Health Care
- Exchange
- RPTX Nasdaq
- ANTX Nasdaq
- Market Cap
- RPTX 38.3M
- ANTX 37.3M
- IPO Year
- RPTX 2020
- ANTX 2022
- Fundamental
- Price
- RPTX $1.40
- ANTX $1.22
- Analyst Decision
- RPTX Strong Buy
- ANTX Buy
- Analyst Count
- RPTX 3
- ANTX 4
- Target Price
- RPTX $4.50
- ANTX $2.00
- AVG Volume (30 Days)
- RPTX 508.5K
- ANTX 134.1K
- Earning Date
- RPTX 05-20-2025
- ANTX 05-16-2025
- Dividend Yield
- RPTX N/A
- ANTX N/A
- EPS Growth
- RPTX N/A
- ANTX N/A
- EPS
- RPTX N/A
- ANTX N/A
- Revenue
- RPTX $53,477,000.00
- ANTX N/A
- Revenue This Year
- RPTX N/A
- ANTX N/A
- Revenue Next Year
- RPTX $7.14
- ANTX N/A
- P/E Ratio
- RPTX N/A
- ANTX N/A
- Revenue Growth
- RPTX 4.58
- ANTX N/A
- 52 Week Low
- RPTX $0.89
- ANTX $0.87
- 52 Week High
- RPTX $4.29
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- RPTX 59.23
- ANTX 45.46
- Support Level
- RPTX $1.25
- ANTX $1.05
- Resistance Level
- RPTX $1.48
- ANTX $1.29
- Average True Range (ATR)
- RPTX 0.11
- ANTX 0.07
- MACD
- RPTX 0.01
- ANTX -0.00
- Stochastic Oscillator
- RPTX 57.14
- ANTX 61.82
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.